Cite
HARVARD Citation
Laffel, L. et al. (2018). Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. Diabetic medicine. 35 (8), pp. 1096-1104. [Online].